{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:22:24Z","timestamp":1789420944860,"version":"build-2803163510"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008977","name":"Universit\u00e4t Ulm","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008977","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Peripheral nerves have an intrinsic capacity for regeneration after traumatic injury, with Schwann cells (SCs) playing a central role in orchestrating this complex process. Critical components of successful regeneration include SC reprogramming into repair SCs, debris removal and metabolic adaptations. Up to now, there are no pharmacological treatments available in the clinics to improve nerve regeneration. In this study, we investigated peroxisome proliferator-activated receptor gamma (PPAR\u0263) as a therapeutic target in the context of nerve regeneration, since we previously found this transcription factor to be involved in SC reprograming and metabolic adaptations. Therefore, we used a mouse model of sciatic nerve crush injury and applied the PPAR\u0263 agonist pioglitazone (PIO) in two different treatment paradigms: (i) acutely after injury (0\u20135 days post injury) and (ii) delayed (5\u201321 days post injury), thereby addressing different phases of regeneration. Our findings revealed that PIO treatment immediately following nerve injury (first treatment paradigm) disrupted SC transition into the repair phenotype and diminished the physiological inflammatory response. As a consequence, axonal and myelin debris clearance was delayed, ultimately resulting in impaired axonal outgrowth and nerve regeneration. In the second treatment paradigm (PIO administration starting five days after injury) SCs had already acquired the repair phenotype and immune cell infiltration had taken place when PIO administration started. There, PIO promoted axonal regeneration, enhanced remyelination, and improved functional recovery. Importantly, PIO treatment increased mitochondrial content in neurons and SCs. In addition, delayed application of PIO induced lipid metabolism, glycolysis and ATP production in SCs, leading to the assumption that improved metabolic conditions mediate enhanced nerve regeneration in this treatment paradigm. These findings show that depending on the timing of PIO treatment, PPAR\u0263 can serve as a potential therapeutic agent to improve nerve regeneration by promoting key metabolic adaptations.<\/jats:p>","DOI":"10.1186\/s13024-025-00913-1","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T17:48:30Z","timestamp":1764611310000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pioglitazone modulates metabolic adaptation and peripheral nerve regeneration after injury"],"prefix":"10.1186","volume":"20","author":[{"given":"Antonia","family":"Seitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylan","family":"\u00d6z\u00f6nc\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Sinske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Klugmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Tews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Fischer-Posovszky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Kn\u00f6ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Meyer zu Reckendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"issue":"3","key":"913_CR1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.4103\/neuroindia.NI_987_16","volume":"65","author":"JA Kouyoumdjian","year":"2017","unstructured":"Kouyoumdjian JA, Graca CR, Ferreira VFM. Peripheral nerve injuries: A retrospective survey of 1124 cases. Neurol India. 2017;65(3):551\u20135.","journal-title":"Neurol India"},{"issue":"1","key":"913_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/00005373-199807000-00025","volume":"45","author":"J Noble","year":"1998","unstructured":"Noble J, Munro CA, Prasad VS, Midha R. Analysis of upper and lower extremity peripheral nerve injuries in a population of patients with multiple injuries. J Trauma. 1998;45(1):116\u201322.","journal-title":"J Trauma"},{"issue":"1","key":"913_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1017\/cjn.2015.312","volume":"43","author":"GM Bray","year":"2016","unstructured":"Bray GM, Huggett DL. Neurological Diseases, disorders and injuries in canada: highlights of a National study. Can J Neurol Sci. 2016;43(1):5\u201314.","journal-title":"Can J Neurol Sci"},{"key":"913_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.expneurol.2017.01.009","volume":"290","author":"WA Palispis","year":"2017","unstructured":"Palispis WA, Gupta R. Surgical repair in humans after traumatic nerve injury provides limited functional neural regeneration in adults. Exp Neurol. 2017;290:106\u201314.","journal-title":"Exp Neurol"},{"key":"913_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1146\/annurev.ne.13.030190.000355","volume":"13","author":"JW Fawcett","year":"1990","unstructured":"Fawcett JW, Keynes RJ. Peripheral nerve regeneration. Annu Rev Neurosci. 1990;13:43\u201360.","journal-title":"Annu Rev Neurosci"},{"issue":"1","key":"913_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.pneurobio.2012.05.005","volume":"98","author":"I Allodi","year":"2012","unstructured":"Allodi I, Udina E, Navarro X. Specificity of peripheral nerve regeneration: interactions at the axon level. Prog Neurobiol. 2012;98(1):16\u201337.","journal-title":"Prog Neurobiol"},{"key":"913_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/B978-0-444-52902-2.00005-9","volume":"115","author":"GJ Kidd","year":"2013","unstructured":"Kidd GJ, Ohno N, Trapp BD. Biology of Schwann cells. Handb Clin Neurol. 2013;115:55\u201379.","journal-title":"Handb Clin Neurol"},{"issue":"4","key":"913_CR8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.neuron.2012.06.021","volume":"75","author":"PJ Arthur-Farraj","year":"2012","unstructured":"Arthur-Farraj PJ, Latouche M, Wilton DK, Quintes S, Chabrol E, Banerjee A, et al. c-Jun reprograms Schwann cells of injured nerves to generate a repair cell essential for regeneration. Neuron. 2012;75(4):633\u201347.","journal-title":"Neuron"},{"issue":"13","key":"913_CR9","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1113\/JP270874","volume":"594","author":"KR Jessen","year":"2016","unstructured":"Jessen KR, Mirsky R. The repair Schwann cell and its function in regenerating nerves. J Physiol. 2016;594(13):3521\u201331.","journal-title":"J Physiol"},{"issue":"37","key":"913_CR10","doi-asserted-by":"publisher","first-page":"9086","DOI":"10.1523\/JNEUROSCI.1453-17.2017","volume":"37","author":"JA Gomez-Sanchez","year":"2017","unstructured":"Gomez-Sanchez JA, Pilch KS, van der Lans M, Fazal SV, Benito C, Wagstaff LJ, et al. After nerve Injury, lineage tracing shows that Myelin and Remak Schwann cells elongate extensively and branch to form repair Schwann cells, which shorten radically on remyelination. J Neurosci. 2017;37(37):9086\u201399.","journal-title":"J Neurosci"},{"issue":"9","key":"913_CR11","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.cmet.2021.07.017","volume":"33","author":"SA Eming","year":"2021","unstructured":"Eming SA, Murray PJ, Pearce EJ. Metabolic orchestration of the wound healing response. Cell Metab. 2021;33(9):1726\u201343.","journal-title":"Cell Metab"},{"issue":"1","key":"913_CR12","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1038\/s41467-020-15915-4","volume":"11","author":"S Meyer Zu Reckendorf","year":"2020","unstructured":"Meyer Zu Reckendorf S, Brand C, Pedro MT, Hegler J, Schilling CS, Lerner R, et al. Lipid metabolism adaptations are reduced in human compared to murine Schwann cells following injury. Nat Commun. 2020;11(1):2123.","journal-title":"Nat Commun"},{"issue":"12","key":"913_CR13","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/j.cmet.2023.10.017","volume":"35","author":"VK Sundaram","year":"2023","unstructured":"Sundaram VK, Schutza V, Schroter NH, Backhaus A, Bilsing A, Joneck L, et al. Adipo-glial signaling mediates metabolic adaptation in peripheral nerve regeneration. Cell Metab. 2023;35(12):2136\u2013e529.","journal-title":"Cell Metab"},{"issue":"8","key":"913_CR14","doi-asserted-by":"publisher","first-page":"5495","DOI":"10.1128\/MCB.19.8.5495","volume":"19","author":"L Fajas","year":"1999","unstructured":"Fajas L, Schoonjans K, Gelman L, Kim JB, Najib J, Martin G, et al. Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1\/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol Cell Biol. 1999;19(8):5495\u2013503.","journal-title":"Mol Cell Biol"},{"issue":"4","key":"913_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1358\/dnp.2004.17.4.829049","volume":"17","author":"S Sundararajan","year":"2004","unstructured":"Sundararajan S, Landreth GE. Antiinflammatory properties of PPARgamma agonists following ischemia. Drug News Perspect. 2004;17(4):229\u201336.","journal-title":"Drug News Perspect"},{"issue":"2","key":"913_CR16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1471-4159.2006.03758.x","volume":"97","author":"Y Luo","year":"2006","unstructured":"Luo Y, Yin W, Signore AP, Zhang F, Hong Z, Wang S, et al. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist Rosiglitazone. J Neurochem. 2006;97(2):435\u201348.","journal-title":"J Neurochem"},{"issue":"4","key":"913_CR17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1358\/dnp.2010.23.4.1437710","volume":"23","author":"RK Kaundal","year":"2010","unstructured":"Kaundal RK, Sharma SS. Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents. Drug News Perspect. 2010;23(4):241\u201356.","journal-title":"Drug News Perspect"},{"key":"913_CR18","doi-asserted-by":"publisher","first-page":"517162","DOI":"10.1155\/2008\/517162","volume":"2008","author":"DM McTigue","year":"2008","unstructured":"McTigue DM. Potential therapeutic targets for PPARgamma after spinal cord injury. PPAR Res. 2008;2008:517162.","journal-title":"PPAR Res"},{"issue":"3","key":"913_CR19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/01.j.pain.0000460333.79127.be","volume":"156","author":"RB Griggs","year":"2015","unstructured":"Griggs RB, Donahue RR, Morgenweck J, Grace PM, Sutton A, Watkins LR, et al. Pioglitazone rapidly reduces neuropathic pain through astrocyte and nongenomic PPARgamma mechanisms. Pain. 2015;156(3):469\u201382.","journal-title":"Pain"},{"issue":"8","key":"913_CR20","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1179\/016164110X12556180206112","volume":"32","author":"Q Zhang","year":"2010","unstructured":"Zhang Q, Hu W, Meng B, Tang T. PPARgamma agonist Rosiglitazone is neuroprotective after traumatic spinal cord injury via anti-inflammatory in adult rats. Neurol Res. 2010;32(8):852\u20139.","journal-title":"Neurol Res"},{"issue":"1","key":"913_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/0300060513476601","volume":"41","author":"X Li","year":"2013","unstructured":"Li X, Du J, Xu S, Lin X, Ling Z. Peroxisome proliferator-activated receptor-gamma agonist Rosiglitazone reduces secondary damage in experimental spinal cord injury. J Int Med Res. 2013;41(1):153\u201361.","journal-title":"J Int Med Res"},{"issue":"4","key":"913_CR22","doi-asserted-by":"publisher","first-page":"710","DOI":"10.2337\/diacare.24.4.710","volume":"24","author":"Y Miyazaki","year":"2001","unstructured":"Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with Pioglitazone. Diabetes Care. 2001;24(4):710\u20139.","journal-title":"Diabetes Care"},{"issue":"2","key":"913_CR23","doi-asserted-by":"publisher","first-page":"fcad032","DOI":"10.1093\/braincomms\/fcad032","volume":"5","author":"WB Hubbard","year":"2023","unstructured":"Hubbard WB, Vekaria HJ, Kalimon OJ, Spry ML, Brown EP, Kilbaugh TJ, et al. Pioglitazone restores mitochondrial function but does not spare cortical tissue following mild brain contusion. Brain Commun. 2023;5(2):fcad032.","journal-title":"Brain Commun"},{"issue":"1","key":"913_CR24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.expneurol.2010.10.003","volume":"227","author":"A Sauerbeck","year":"2011","unstructured":"Sauerbeck A, Gao J, Readnower R, Liu M, Pauly JR, Bing G, et al. Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. Exp Neurol. 2011;227(1):128\u201335.","journal-title":"Exp Neurol"},{"key":"913_CR25","doi-asserted-by":"publisher","first-page":"113243","DOI":"10.1016\/j.expneurol.2020.113243","volume":"327","author":"HM Yonutas","year":"2020","unstructured":"Yonutas HM, Hubbard WB, Pandya JD, Vekaria HJ, Geldenhuys WJ, Sullivan PG. Bioenergetic restoration and neuroprotection after therapeutic targeting of mitoneet: new mechanism of Pioglitazone following traumatic brain injury. Exp Neurol. 2020;327:113243.","journal-title":"Exp Neurol"},{"issue":"2","key":"913_CR26","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.expneurol.2007.02.009","volume":"205","author":"DM McTigue","year":"2007","unstructured":"McTigue DM, Tripathi R, Wei P, Lash AT. The PPAR gamma agonist Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury. Exp Neurol. 2007;205(2):396\u2013406.","journal-title":"Exp Neurol"},{"issue":"6","key":"913_CR27","first-page":"353","volume":"2","author":"S Iwai","year":"2008","unstructured":"Iwai S, Maeda T, Kiguchi N, Kobayashi Y, Fukazawa Y, Ozaki M, et al. Pioglitazone attenuates tactile allodynia and microglial activation in mice with peripheral nerve injury. Drug Discov Ther. 2008;2(6):353\u20136.","journal-title":"Drug Discov Ther"},{"key":"913_CR28","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.neulet.2013.03.046","volume":"543","author":"HB Jia","year":"2013","unstructured":"Jia HB, Wang XM, Qiu LL, Liu XY, Shen JC, Ji Q, et al. Spinal neuroimmune activation inhibited by repeated administration of Pioglitazone in rats after L5 spinal nerve transection. Neurosci Lett. 2013;543:130\u20135.","journal-title":"Neurosci Lett"},{"issue":"1","key":"913_CR29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nprot.2006.486","volume":"2","author":"K Haastert","year":"2007","unstructured":"Haastert K, Mauritz C, Chaturvedi S, Grothe C. Human and rat adult Schwann cell cultures: fast and efficient enrichment and highly effective non-viral transfection protocol. Nat Protoc. 2007;2(1):99\u2013104.","journal-title":"Nat Protoc"},{"issue":"10","key":"913_CR30","doi-asserted-by":"publisher","first-page":"e56380","DOI":"10.15252\/embr.202256380","volume":"24","author":"BR Desousa","year":"2023","unstructured":"Desousa BR, Kim KK, Jones AE, Ball AB, Hsieh WY, Swain P, et al. Calculation of ATP production rates using the seahorse XF analyzer. EMBO Rep. 2023;24(10):e56380.","journal-title":"EMBO Rep"},{"issue":"2","key":"913_CR31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/(SICI)1098-2752(1998)18:2<119::AID-MICR10>3.0.CO;2-0","volume":"18","author":"MM Inserra","year":"1998","unstructured":"Inserra MM, Bloch DA, Terris DJ. Functional indices for sciatic, peroneal, and posterior tibial nerve lesions in the mouse. Microsurgery. 1998;18(2):119\u201324.","journal-title":"Microsurgery"},{"issue":"4","key":"913_CR32","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.cmet.2014.08.003","volume":"20","author":"N Srivastava","year":"2014","unstructured":"Srivastava N, Kollipara RK, Singh DK, Sudderth J, Hu Z, Nguyen H, et al. Inhibition of cancer cell proliferation by PPARgamma is mediated by a metabolic switch that increases reactive oxygen species levels. Cell Metab. 2014;20(4):650\u201361.","journal-title":"Cell Metab"},{"issue":"8","key":"913_CR33","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.2337\/diabetes.54.8.2305","volume":"54","author":"GB Di Gregorio","year":"2005","unstructured":"Di Gregorio GB, Yao-Borengasser A, Rasouli N, Varma V, Lu T, Miles LM, et al. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by Pioglitazone. Diabetes. 2005;54(8):2305\u201313.","journal-title":"Diabetes"},{"key":"913_CR34","doi-asserted-by":"publisher","first-page":"538183","DOI":"10.1155\/2014\/538183","volume":"2014","author":"J Peng","year":"2014","unstructured":"Peng J, Huan Y, Jiang Q, Sun SJ, Jia CM, Shen ZF. Effects and potential mechanisms of Pioglitazone on lipid metabolism in obese diabetic KKAy mice. PPAR Res. 2014;2014:538183.","journal-title":"PPAR Res"},{"issue":"4","key":"913_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12032-015-0536-8","volume":"32","author":"X Ren","year":"2015","unstructured":"Ren X, Zheng D, Guo F, Liu J, Zhang B, Li H, et al. PPARgamma suppressed Wnt\/beta-catenin signaling pathway and its downstream effector SOX9 expression in gastric cancer cells. Med Oncol. 2015;32(4):91.","journal-title":"Med Oncol"},{"issue":"1","key":"913_CR36","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13046-019-1176-1","volume":"38","author":"V Ciaramella","year":"2019","unstructured":"Ciaramella V, Sasso FC, Di Liello R, Corte CMD, Barra G, Viscardi G, et al. Activity and molecular targets of Pioglitazone via Blockade of proliferation, invasiveness and bioenergetics in human NSCLC. J Exp Clin Cancer Res. 2019;38(1):178.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"913_CR37","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12885-019-5426-6","volume":"19","author":"S Lv","year":"2019","unstructured":"Lv S, Wang W, Wang H, Zhu Y, Lei C. PPARgamma activation serves as therapeutic strategy against bladder cancer via inhibiting PI3K-Akt signaling pathway. BMC Cancer. 2019;19(1):204.","journal-title":"BMC Cancer"},{"issue":"3","key":"913_CR38","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1529-8027.2008.00183.x","volume":"13","author":"M Eto","year":"2008","unstructured":"Eto M, Sumi H, Fujimura H, Yoshikawa H, Sakoda S. Pioglitazone promotes peripheral nerve remyelination after crush injury through CD36 upregulation. J Peripher Nerv Syst. 2008;13(3):242\u20138.","journal-title":"J Peripher Nerv Syst"},{"key":"913_CR39","doi-asserted-by":"crossref","unstructured":"Gey M, Wanner R, Schilling C, Pedro MT, Sinske D, Knoll B. Atf3 mutant mice show reduced axon regeneration and impaired regeneration-associated gene induction after peripheral nerve injury. Open Biol. 2016;6(8).","DOI":"10.1098\/rsob.160091"},{"key":"913_CR40","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.freeradbiomed.2016.06.023","volume":"100","author":"JC Corona","year":"2016","unstructured":"Corona JC, Duchen MR. PPARgamma as a therapeutic target to rescue mitochondrial function in neurological disease. Free Radic Biol Med. 2016;100:153\u201363.","journal-title":"Free Radic Biol Med"},{"issue":"5","key":"913_CR41","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.neuron.2013.01.012","volume":"77","author":"A Viader","year":"2013","unstructured":"Viader A, Sasaki Y, Kim S, Strickland A, Workman CS, Yang K, et al. Aberrant Schwann cell lipid metabolism linked to mitochondrial deficits leads to axon degeneration and neuropathy. Neuron. 2013;77(5):886\u201398.","journal-title":"Neuron"},{"issue":"9","key":"913_CR42","doi-asserted-by":"publisher","first-page":"e106992","DOI":"10.1371\/journal.pone.0106992","volume":"9","author":"BH Shamsi","year":"2014","unstructured":"Shamsi BH, Ma C, Naqvi S, Xiao Y. Effects of Pioglitazone mediated activation of PPAR-gamma on CIDEC and obesity related changes in mice. PLoS ONE. 2014;9(9):e106992.","journal-title":"PLoS ONE"},{"issue":"1","key":"913_CR43","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1523\/JNEUROSCI.14-01-00357.1994","volume":"14","author":"JF Goodrum","year":"1994","unstructured":"Goodrum JF, Earnhardt T, Goines N, Bouldin TW. Fate of Myelin lipids during degeneration and regeneration of peripheral nerve: an autoradiographic study. J Neurosci. 1994;14(1):357\u201367.","journal-title":"J Neurosci"},{"key":"913_CR44","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/ncomms2270","volume":"3","author":"Y Hou","year":"2012","unstructured":"Hou Y, Moreau F, Chadee K. PPARgamma is an E3 ligase that induces the degradation of NFkappaB\/p65. Nat Commun. 2012;3:1300.","journal-title":"Nat Commun"},{"issue":"4","key":"913_CR45","first-page":"283","volume":"3","author":"L Qi","year":"2010","unstructured":"Qi L, Jacob A, Wang P, Wu R. Peroxisome proliferator activated receptor-gamma and traumatic brain injury. Int J Clin Exp Med. 2010;3(4):283\u201392.","journal-title":"Int J Clin Exp Med"},{"issue":"5","key":"913_CR46","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1159\/000530621","volume":"45","author":"J Wang","year":"2023","unstructured":"Wang J, Chen H, Hou W, Han Q, Wang Z. Hippo pathway in Schwann cells and regeneration of peripheral nervous system. Dev Neurosci. 2023;45(5):276\u201389.","journal-title":"Dev Neurosci"},{"key":"913_CR47","doi-asserted-by":"crossref","unstructured":"Grove M, Kim H, Santerre M, Krupka AJ, Han SB, Zhai J, et al. YAP\/TAZ initiate and maintain Schwann cell myelination. Elife. 2017;6.","DOI":"10.7554\/eLife.20982"},{"issue":"6","key":"913_CR48","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1158\/2159-8290.CD-13-0081","volume":"3","author":"AL Watson","year":"2013","unstructured":"Watson AL, Rahrmann EP, Moriarity BS, Choi K, Conboy CB, Greeley AD, et al. Canonical Wnt\/beta-catenin signaling drives human Schwann cell transformation, progression, and tumor maintenance. Cancer Discov. 2013;3(6):674\u201389.","journal-title":"Cancer Discov"},{"issue":"4","key":"913_CR49","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1471-4159.2012.07706.x","volume":"121","author":"CA Ruff","year":"2012","unstructured":"Ruff CA, Staak N, Patodia S, Kaswich M, Rocha-Ferreira E, Da Costa C, et al. Neuronal c-Jun is required for successful axonal regeneration, but the effects of phosphorylation of its N-terminus are moderate. J Neurochem. 2012;121(4):607\u201318.","journal-title":"J Neurochem"},{"issue":"7203","key":"913_CR50","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/nature07202","volume":"454","author":"SJ Bensinger","year":"2008","unstructured":"Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature. 2008;454(7203):470\u20137.","journal-title":"Nature"},{"key":"913_CR51","doi-asserted-by":"publisher","first-page":"107705","DOI":"10.1016\/j.pharmthera.2020.107705","volume":"219","author":"S Jamwal","year":"2021","unstructured":"Jamwal S, Blackburn JK, Elsworth JD. PPARgamma\/PGC1alpha signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders. Pharmacol Ther. 2021;219:107705.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"913_CR52","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.2337\/diabetes.54.5.1392","volume":"54","author":"I Bogacka","year":"2005","unstructured":"Bogacka I, Xie H, Bray GA, Smith SR. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes. 2005;54(5):1392\u20139.","journal-title":"Diabetes"},{"key":"913_CR53","doi-asserted-by":"publisher","first-page":"650038","DOI":"10.3389\/fnagi.2021.650038","volume":"13","author":"B Wang","year":"2021","unstructured":"Wang B, Huang M, Shang D, Yan X, Zhao B, Zhang X. Mitochondrial behavior in axon degeneration and regeneration. Front Aging Neurosci. 2021;13:650038.","journal-title":"Front Aging Neurosci"},{"key":"913_CR54","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3389\/fncel.2020.00148","volume":"14","author":"F Boucanova","year":"2020","unstructured":"Boucanova F, Chrast R. Metabolic interaction between Schwann cells and axons under physiological and disease conditions. Front Cell Neurosci. 2020;14:148.","journal-title":"Front Cell Neurosci"},{"issue":"11","key":"913_CR55","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.7150\/ijbs.98387","volume":"20","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhang R, Chen Q, Lei Z, Shi C, Pang Y, et al. PPARgamma agonist Pioglitazone prevents Hypoxia-induced cardiac dysfunction by reprogramming glucose metabolism. Int J Biol Sci. 2024;20(11):4297\u2013313.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"913_CR56","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/glia.24620","volume":"73","author":"A Schneider","year":"2025","unstructured":"Schneider A, Won S, Armstrong EA, Cooper AJ, Suresh A, Rivera R, et al. The role of ATP citrate lyase in Myelin formation and maintenance. Glia. 2025;73(1):105\u201321.","journal-title":"Glia"},{"issue":"12","key":"913_CR57","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1016\/j.celrep.2015.08.039","volume":"12","author":"D Ino","year":"2015","unstructured":"Ino D, Sagara H, Suzuki J, Kanemaru K, Okubo Y, Iino M. Neuronal regulation of Schwann cell mitochondrial Ca(2+) signaling during myelination. Cell Rep. 2015;12(12):1951\u20139.","journal-title":"Cell Rep"},{"key":"913_CR58","doi-asserted-by":"crossref","unstructured":"Dimas P, Montani L, Pereira JA, Moreno D, Trotzmuller M, Gerber J, et al. CNS myelination and remyelination depend on fatty acid synthesis by oligodendrocytes. Elife. 2019;8.","DOI":"10.7554\/eLife.44702"},{"issue":"4","key":"913_CR59","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1083\/jcb.201706010","volume":"217","author":"L Montani","year":"2018","unstructured":"Montani L, Pereira JA, Norrmen C, Pohl HBF, Tinelli E, Trotzmuller M, et al. De Novo fatty acid synthesis by Schwann cells is essential for peripheral nervous system myelination. J Cell Biol. 2018;217(4):1353\u201368.","journal-title":"J Cell Biol"},{"issue":"SupplSuppl","key":"913_CR60","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1194\/jlr.R800085-JLR200","volume":"50","author":"IJ Goldberg","year":"2009","unstructured":"Goldberg IJ, Eckel RH, Abumrad NA. Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-mediated pathways. J Lipid Res. 2009;50(SupplSuppl):S86\u201390.","journal-title":"J Lipid Res"},{"issue":"1","key":"913_CR61","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.endonu.2012.03.005","volume":"60","author":"N Hernandez-Beltran","year":"2013","unstructured":"Hernandez-Beltran N, Moreno CB, Gutierrez-Alvarez AM. Contribution of mitochondria to pain in diabetic neuropathy. Endocrinol Nutr. 2013;60(1):25\u201332.","journal-title":"Endocrinol Nutr"},{"issue":"9","key":"913_CR62","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1111\/jdi.13544","volume":"12","author":"G Ponirakis","year":"2021","unstructured":"Ponirakis G, Abdul-Ghani MA, Jayyousi A, Zirie MA, Qazi M, Almuhannadi H, et al. Painful diabetic neuropathy is associated with increased nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control. J Diabetes Investig. 2021;12(9):1642\u201350.","journal-title":"J Diabetes Investig"},{"key":"913_CR63","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/B978-0-12-821751-1.00014-2","volume":"194","author":"R Horvath","year":"2023","unstructured":"Horvath R, Medina J, Reilly MM, Shy ME, Zuchner S. Peripheral neuropathy in mitochondrial disease. Handb Clin Neurol. 2023;194:99\u2013116.","journal-title":"Handb Clin Neurol"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00913-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-025-00913-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00913-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T19:02:13Z","timestamp":1764615733000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-025-00913-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["913"],"URL":"https:\/\/doi.org\/10.1186\/s13024-025-00913-1","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}